U.S. National Cancer Institute

The U.S. National Cancer Institute (NCI) is a long-time, committed research and clinical development partner. Our collaboration efforts began under Dr. Rosenberg’s immunology laboratory and continue today with the endocrine oncology branch of the cancer center. Dr. Steven Libutti, formerly a surgeon at the NCI and now the director of the Rutgers Cancer Institute of New Jersey, conducted CytImmune’s phase 1 clinical trial. Oncologist and surgeon Dr. Naris Nilubol will be managing CytImmune’s upcoming clinical studies at the NCI. Included in these studies will be efficacy assessments of CYT-6091 in combination with nab-paclitaxel (Abraxane). We anticipate these studies will begin in late 2021 or early 2022.